Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
This is the last of six podcasts produced from the two hour program we did in partnership with the LUNGevity Foundation earlier this year in Santa Monica, at the start of the "Targeted Therapies in Lung Cancer" annual meeting. This activity was comprised of some great panel discussions and brief presentations on tough but timely issues on the subject of "Molecular Markers in Advanced NSCLC: Who to Test and What to Test For?". It featured guest faculty members Dr. Charlie Rudin from Johns Hopkins University, Dr. Alice Shaw from Massachusetts General Hospital, Dr. David Spigel from Sarah Cannon Cancer Center, and Dr. Glen Goss from the University of Ottawa.
In this last installment, Dr. Goss speaks on the topic of how to broaden the incorporation of molecular marker studies in lung cancer beyond specialty academic centers and try to implement them in wider networks. He discusses the early pilot efforts as well as the challenges, particular cost issues, but raises the possibility that smarter treatment could also prove to be more cost-effective, even adding the cost of more and better molecular diagnostic studies.
We follow his presentations with some final meaty questions about the panels views on what role physicians should play in considering costs of health care recommendations, whether we should be doing "reflex testing" automatically for all patients with advanced NSCLC (or a defined subset), and whether there's a clear role and incentive for repeat biopsies over the course of ongoing treatment.
Here are the audio and video versions of the podcast, along with transcript and figures.
Molecular Markers SM Pt 6 Goss on Markers in HC Systems Audio Podcast
Molecular Markers SM Pt 6 Goss on Markers in HC Systems Transcript
Molecular Markers SM Pt 6 Goss on Markers in HC Systems Figs
Our next podcasts will cover presentations by Drs. Ramaswamy Govindan and Julie Brahmer on Immunotherapies for Lung Cancer. There should be some news on this front from ASCO, particularly on anti-PD1 as a mechanism, so we'll work to get that content out around the time we're discussing the new information being presented at ASCO.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi Stan, It's good to hear your voice and know your cheesecakes are still making the rounds. Though I'm sure startling, I imagine some of those little pockets of the house...
Hi Rutbats, Welcome to GRACE and thanks for the kind words.
We can't say what you should or shouldn't do and I can't say why your RA doc made their...
Thank you very much for your quick answer, Janine.
I have an appointment with a pulmonologist in 10 days. I will summarize the conversation with him here, so that other people...
Glad to know you're moving forward with a pulmonologist. The more you know the better the conversation with your pulmonologist. Remember you can help your docs know what level their conversation...
Hi Terry, Welcome to Grace.
I saw this exact post somewhere else months back and the only response was to a lab. I hope that doesn't happen here, we don't allow...
Stan - Thank you once again for your kind words. Thank you as well for your donation. As you know, your donation helps us to exist and continue to fulfill our...